A citation-based method for searching scientific literature

Kathleen E Malone, Colin B Begg, Robert W Haile, Ake Borg, Patrick Concannon, Lina Tellhed, Shanyan Xue, Sharon Teraoka, Leslie Bernstein, Marinela Capanu, Anne S Reiner, Elyn R Riedel, Duncan C Thomas, Lene Mellemkjaer, Charles F Lynch, John D Boice, Hoda Anton-Culver, Jonine L Bernstein. J Clin Oncol 2010
Times Cited: 111







List of co-cited articles
647 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Monika K Graeser, Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G Froster, Bettina Schlehe, Astrid Bechtold, Norbert Arnold,[...]. J Clin Oncol 2009
194
42

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Ivo Olivotto, Ellen Warner, Olufunmilayo I Olopade, Andrea Eisen, Barbara Weber, Jane McLennan,[...]. J Clin Oncol 2004
424
32

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
882
26

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
K Metcalfe, S Gershman, H T Lynch, P Ghadirian, N Tung, C Kim-Sing, O I Olopade, S Domchek, J McLennan, A Eisen,[...]. Br J Cancer 2011
126
24

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
22

Epidemiology of contralateral breast cancer.
Y Chen, W Thompson, R Semenciw, Y Mao. Cancer Epidemiol Biomarkers Prev 1999
244
20

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
148
19

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
19

Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Lori J Pierce, Albert M Levin, Timothy R Rebbeck, Merav A Ben-David, Eitan Friedman, Lawrence J Solin, Eleanor E Harris, David K Gaffney, Bruce G Haffty, Laura A Dawson,[...]. J Clin Oncol 2006
211
19

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Jacek Gronwald, Nadine Tung, William D Foulkes, Kenneth Offit, Ruth Gershoni, Mary Daly, Charmaine Kim-Sing, Hakan Olsson, Peter Ainsworth, Andrea Eisen,[...]. Int J Cancer 2006
177
18

Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.
Jonine L Bernstein, Bryan Langholz, Robert W Haile, Leslie Bernstein, Duncan C Thomas, Marilyn Stovall, Kathleen E Malone, Charles F Lynch, Jørgen H Olsen, Hoda Anton-Culver,[...]. Breast Cancer Res 2004
87
16


Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Kerryn W Reding, Jonine L Bernstein, Bryan M Langholz, Leslie Bernstein, Robert W Haile, Colin B Begg, Charles F Lynch, Patrick Concannon, Ake Borg, Sharon N Teraoka,[...]. Breast Cancer Res Treat 2010
40
35

Second primary breast cancer occurrence according to hormone receptor status.
Allison W Kurian, Laura A McClure, Esther M John, Pamela L Horn-Ross, James M Ford, Christina A Clarke. J Natl Cancer Inst 2009
82
17

Variation of breast cancer risk among BRCA1/2 carriers.
Colin B Begg, Robert W Haile, Ake Borg, Kathleen E Malone, Patrick Concannon, Duncan C Thomas, Bryan Langholz, Leslie Bernstein, Jørgen H Olsen, Charles F Lynch,[...]. JAMA 2008
208
13

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin,[...]. Breast Cancer Res 2004
212
13

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Anne S Reiner, Esther M John, Jennifer D Brooks, Charles F Lynch, Leslie Bernstein, Lene Mellemkjær, Kathleen E Malone, Julia A Knight, Marinela Capanu, Sharon N Teraoka,[...]. J Clin Oncol 2013
77
16

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
528
13

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
12

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Bruce G Haffty, Elizabeth Harrold, Atif J Khan, Pradip Pathare, Tanya E Smith, Bruce C Turner, Peter M Glazer, Barbara Ward, Daryl Carter, Ellen Matloff,[...]. Lancet 2002
198
12

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Chanita Hughes Halbert, Tiffani DeMarco, William Lawrence, David Main, Clinton Finch, Colette Magnant,[...]. J Clin Oncol 2004
193
12

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Dorina M van der Kolk, Geertruida H de Bock, Beike K Leegte, Michael Schaapveld, Marian J E Mourits, Jakob de Vries, Annemieke H van der Hout, Jan C Oosterwijk. Breast Cancer Res Treat 2010
120
12

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
T C van Sprundel, M K Schmidt, M A Rookus, R Brohet, C J van Asperen, E J Th Rutgers, L J Van't Veer, R A E M Tollenaar. Br J Cancer 2005
183
12

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Lori J Pierce, Kelly-Anne Phillips, Kent A Griffith, Saundra Buys, David K Gaffney, Meena S Moran, Bruce G Haffty, Merav Ben-David, Bella Kaufman, Judy E Garber,[...]. Breast Cancer Res Treat 2010
106
12

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
L C Verhoog, C T Brekelmans, C Seynaeve, E J Meijers-Heijboer, J G Klijn. Br J Cancer 2000
88
12

BRCA-associated breast cancer in young women.
M Robson, T Gilewski, B Haas, D Levin, P Borgen, P Rajan, Y Hirschaut, P Pressman, P P Rosen, M L Lesser,[...]. J Clin Oncol 1998
256
11

Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Carlos A Garcia-Etienne, Monica Barile, Oreste D Gentilini, Edoardo Botteri, Nicole Rotmensz, Andrea Sagona, Gabriel Farante, Viviana Galimberti, Alberto Luini, Paolo Veronesi,[...]. Ann Surg Oncol 2009
58
18

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
113
11

Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis.
Jeffrey N Weitzel, Sarah M McCaffrey, Raluca Nedelcu, Deborah J MacDonald, Kathleen R Blazer, Carey A Cullinane. Arch Surg 2003
120
10

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion Kiechle, Nina Ditsch, Wolfgang Janni, Christoph Mundhenke, Michael Golatta,[...]. Breast Cancer Res 2012
60
16

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
9

Risk of second breast cancer according to estrogen receptor status and family history.
Christine Bouchardy, Simone Benhamou, Gérald Fioretta, Helena M Verkooijen, Pierre O Chappuis, Isabelle Neyroud-Caspar, Monica Castiglione, Vincent Vinh-Hung, Georges Vlastos, Elisabetta Rapiti. Breast Cancer Res Treat 2011
43
20

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
S A Narod, J S Brunet, P Ghadirian, M Robson, K Heimdal, S L Neuhausen, D Stoppa-Lyonnet, C Lerman, B Pasini, P de los Rios,[...]. Lancet 2000
388
9


Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
Douglas E Levy, Stacey D Byfield, Catherine B Comstock, Judy E Garber, Sapna Syngal, William H Crown, Alexandra E Shields. Genet Med 2011
170
9

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Youlia M Kirova, Alexia Savignoni, Brigitte Sigal-Zafrani, Anne de La Rochefordiere, Rémy J Salmon, Pascale This, Bernard Asselain, Dominique Stoppa-Lyonnet, Alain Fourquet. Breast Cancer Res Treat 2010
66
13



Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
L Mellemkjaer, C Dahl, J H Olsen, L Bertelsen, P Guldberg, J Christensen, A-L Børresen-Dale, M Stovall, B Langholz, L Bernstein,[...]. Br J Cancer 2008
31
29

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
722
8

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Charmaine Kim-Sing, Olufunmilayo I Olopade, Susan Domchek, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. Breast Cancer Res Treat 2011
43
18

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
Hazel B Nichols, Amy Berrington de González, James V Lacey, Philip S Rosenberg, William F Anderson. J Clin Oncol 2011
166
8

Survival and prognostic factors in BRCA1-associated breast cancer.
C T M Brekelmans, C Seynaeve, M Menke-Pluymers, H T Brüggenwirth, M M A Tilanus-Linthorst, C C M Bartels, M Kriege, A N van Geel, C M G Crepin, J C Blom,[...]. Ann Oncol 2006
98
8

The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands.
Michael Schaapveld, Otto Visser, W J Louwman, Pax H B Willemse, Elisabeth G E de Vries, Winette T A van der Graaf, Renée Otter, Jan Willem W Coebergh, Flora E van Leeuwen. Breast Cancer Res Treat 2008
81
9

Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
Jonine L Bernstein, Robert W Haile, Marilyn Stovall, John D Boice, Roy E Shore, Bryan Langholz, Duncan C Thomas, Leslie Bernstein, Charles F Lynch, Jorgen H Olsen,[...]. J Natl Cancer Inst 2010
92
8

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
D Gareth R Evans, Sarah L Ingham, Andrew Baildam, Gary L Ross, Fiona Lalloo, Iain Buchan, Anthony Howell. Breast Cancer Res Treat 2013
97
8

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Alexandra J van den Broek, Laura J van 't Veer, Maartje J Hooning, Sten Cornelissen, Annegien Broeks, Emiel J Rutgers, Vincent T H B M Smit, Cees J Cornelisse, Mike van Beek, Maryska L Janssen-Heijnen,[...]. J Clin Oncol 2016
57
14

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
L C Verhoog, C T Brekelmans, C Seynaeve, L M van den Bosch, G Dahmen, A N van Geel, M M Tilanus-Linthorst, C C Bartels, A Wagner, A van den Ouweland,[...]. Lancet 1998
359
7

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Andrea Eisen, Jan Lubinski, Jan Klijn, Pal Moller, Henry T Lynch, Kenneth Offit, Barbara Weber, Tim Rebbeck, Susan L Neuhausen, Parviz Ghadirian,[...]. J Clin Oncol 2005
309
7

Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Claudine Isaacs, Tiffani DeMarco, Chanita Hughes Halbert, Marie Pennanen, Clinton Finch. Cancer Epidemiol Biomarkers Prev 2005
68
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.